JP2012509348A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509348A5
JP2012509348A5 JP2011537624A JP2011537624A JP2012509348A5 JP 2012509348 A5 JP2012509348 A5 JP 2012509348A5 JP 2011537624 A JP2011537624 A JP 2011537624A JP 2011537624 A JP2011537624 A JP 2011537624A JP 2012509348 A5 JP2012509348 A5 JP 2012509348A5
Authority
JP
Japan
Prior art keywords
disease
pharmaceutically acceptable
acceptable salt
composition
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011537624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509348A (ja
JP5535233B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/065188 external-priority patent/WO2010059853A1/en
Publication of JP2012509348A publication Critical patent/JP2012509348A/ja
Publication of JP2012509348A5 publication Critical patent/JP2012509348A5/ja
Application granted granted Critical
Publication of JP5535233B2 publication Critical patent/JP5535233B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011537624A 2008-11-19 2009-11-19 Ｔｇｒ５モジュレーターおよびその使用方法 Expired - Fee Related JP5535233B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08169462 2008-11-19
EP08169462.2 2008-11-19
PCT/US2009/065188 WO2010059853A1 (en) 2008-11-19 2009-11-19 Tgr5 modulators and method of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014088019A Division JP2014159456A (ja) 2008-11-19 2014-04-22 Ｔｇｒ５モジュレーターおよびその使用方法

Publications (3)

Publication Number Publication Date
JP2012509348A JP2012509348A (ja) 2012-04-19
JP2012509348A5 true JP2012509348A5 (enExample) 2012-12-13
JP5535233B2 JP5535233B2 (ja) 2014-07-02

Family

ID=41668454

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011537624A Expired - Fee Related JP5535233B2 (ja) 2008-11-19 2009-11-19 Ｔｇｒ５モジュレーターおよびその使用方法
JP2014088019A Withdrawn JP2014159456A (ja) 2008-11-19 2014-04-22 Ｔｇｒ５モジュレーターおよびその使用方法
JP2015160141A Pending JP2015232020A (ja) 2008-11-19 2015-08-14 Ｔｇｒ５モジュレーターおよびその使用方法
JP2017083045A Withdrawn JP2017132803A (ja) 2008-11-19 2017-04-19 Ｔｇｒ５モジュレーターおよびその使用方法
JP2018059922A Withdrawn JP2018100304A (ja) 2008-11-19 2018-03-27 Ｔｇｒ５モジュレーターおよびその使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014088019A Withdrawn JP2014159456A (ja) 2008-11-19 2014-04-22 Ｔｇｒ５モジュレーターおよびその使用方法
JP2015160141A Pending JP2015232020A (ja) 2008-11-19 2015-08-14 Ｔｇｒ５モジュレーターおよびその使用方法
JP2017083045A Withdrawn JP2017132803A (ja) 2008-11-19 2017-04-19 Ｔｇｒ５モジュレーターおよびその使用方法
JP2018059922A Withdrawn JP2018100304A (ja) 2008-11-19 2018-03-27 Ｔｇｒ５モジュレーターおよびその使用方法

Country Status (23)

Country Link
US (5) US8114862B2 (enExample)
EP (2) EP2698375B1 (enExample)
JP (5) JP5535233B2 (enExample)
KR (2) KR101667436B1 (enExample)
CN (2) CN102325784B (enExample)
AU (1) AU2009316566B9 (enExample)
BR (1) BRPI0921983B8 (enExample)
CA (1) CA2744189C (enExample)
DK (2) DK2376519T3 (enExample)
EA (2) EA030681B1 (enExample)
ES (2) ES2663948T3 (enExample)
HK (1) HK1205132A1 (enExample)
HU (1) HUE039171T2 (enExample)
IL (3) IL212969A (enExample)
LT (1) LT2698375T (enExample)
MX (1) MX2011005295A (enExample)
NO (1) NO2698375T3 (enExample)
PL (2) PL2698375T3 (enExample)
PT (2) PT2698375T (enExample)
SG (1) SG10201400162QA (enExample)
SI (1) SI2698375T1 (enExample)
WO (1) WO2010059853A1 (enExample)
ZA (1) ZA201104077B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1392714T3 (da) 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
DK1734970T3 (en) 2004-03-12 2015-02-16 Intercept Pharmaceuticals Inc Treatment of fibrosis using FXR ligands
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
KR101555716B1 (ko) 2007-01-19 2015-09-25 인터셉트 파마슈티컬즈, 인크. Ｔｇｒ5 조절제로서의 23-치환 담즙산 및 이의 사용 방법
BRPI0916735B8 (pt) 2008-07-30 2021-05-25 Intercept Pharmaceuticals Inc compostos moduladores de tgr5, composições farmacêuticas compreendendo os mesmos e seus usos
PL2698375T3 (pl) * 2008-11-19 2018-08-31 Intercept Pharmaceuticals, Inc. Modulatory TGR5 i sposób ich zastosowania
JP2012509891A (ja) 2008-11-26 2012-04-26 サティオゲン ファーマシューティカルズ，インク． 肥満症及び糖尿病を治療するための胆汁酸再循環阻害剤
CN102316889B (zh) * 2008-11-26 2014-11-26 萨蒂奥根制药公司 组合物及使用方法
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
PL2771003T3 (pl) 2011-10-28 2017-10-31 Lumena Pharmaceuticals Llc Inhibitory ponownego wykorzystania kwasów żółciowych do leczenia pediatrycznych cholestatycznych chorób wątroby
KR20210131431A (ko) 2011-10-28 2021-11-02 샤이어 휴먼 지네틱 테라피즈 인크. 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
WO2013192097A1 (en) 2012-06-19 2013-12-27 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
WO2014059008A1 (en) 2012-10-09 2014-04-17 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
CN104703585A (zh) 2012-10-09 2015-06-10 宝洁公司 鉴定协同化妆品组合的方法
EP3004132A4 (en) 2013-06-06 2017-01-18 Yissum, Research Development Company of the Hebrew Bile acid-basic amino acid conjugates and uses thereof
WO2014200349A1 (en) 2013-06-13 2014-12-18 Fast Forward Pharmaceutical B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
KR102688720B1 (ko) 2013-11-22 2024-07-29 미나 테라퓨틱스 리미티드 Ｃ/ｅｂｐ 알파 짧은 활성화 ｒｎａ 조성물 및 사용 방법
KR102491556B1 (ko) * 2014-05-29 2023-01-25 바 파마슈티컬스 에스.알.엘. Fxr 및 tgr5/gpbar1 매개 질환의 치료 및/또는 예방에 사용하기 위한 콜란 유도체
US20180236064A1 (en) * 2014-10-03 2018-08-23 Mayo Foundation For Medical Education And Research Targeting tgr5 to treat disease
SG11201703717SA (en) * 2014-11-06 2017-06-29 Enanta Pharm Inc Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
DK3221332T3 (da) 2014-11-19 2019-07-29 Nzp Uk Ltd Fremstilling af steroide fxr-modulatorer
CN107207558B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的6α-烷基-6,7-二酮类固醇
DK3221333T3 (da) 2014-11-19 2019-09-30 Nzp Uk Ltd 6-alfa-alkyl-3,7-dionsteroider som mellemprodukter til fremstilling af steroide FXR-modulatorer
WO2016079517A1 (en) 2014-11-19 2016-05-26 Dextra Laboratories Limited 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
CN105985396A (zh) * 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
JP2018519246A (ja) * 2015-04-28 2018-07-19 ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド コール酸誘導体、及びその製造方法及び医薬用途
ES2873088T3 (es) 2015-06-19 2021-11-03 Intercept Pharmaceuticals Inc Moduladores de TGR5 y métodos para su uso
PT3310801T (pt) * 2015-06-24 2021-06-18 Intercept Pharmaceuticals Inc Moduladores de tgr5 e métodos de utilização dos mesmos
EP3353189A4 (en) * 2015-09-24 2019-06-19 Intercept Pharmaceuticals, Inc. METHOD AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF GALLENIC ACID DERIVATIVES
US11034717B2 (en) 2015-10-07 2021-06-15 Intercept Pharmaceuticals, Inc. Farnesoid X receptor modulators
CN106008639B (zh) * 2016-03-11 2019-01-08 深圳市塔吉瑞生物医药有限公司 用于预防或治疗fxr-介导疾病的胆烷酸化合物
WO2017180577A1 (en) 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating cancer
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
EP3465218A4 (en) 2016-05-29 2020-06-17 Human Metabolomics Institute, Inc. BIOMARKERS RELATED TO HEPATIC DISEASES AND METHODS OF USE
WO2018005794A2 (en) * 2016-07-01 2018-01-04 Venenum Biodesign Llc Novel non-systemic tgr5 agonists
WO2018222701A1 (en) * 2017-05-30 2018-12-06 Intercept Pharmaceuticals, Inc. Treatment of renal diseases with a bile acid derivative
CN109021056B (zh) * 2017-06-09 2021-03-09 博瑞生物医药（苏州）股份有限公司 法尼酯x受体激动剂
US11472831B2 (en) 2017-07-24 2022-10-18 Intercept Pharmaceuticals, Inc. Isotopically labeled bile acid derivatives
CA3075205A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
WO2020163201A1 (en) * 2019-02-04 2020-08-13 Intercept Pharmaceuticals, Inc. Treatment and prevention of intestinal inflammatory diseases with a bile acid derivative
CN116925168A (zh) 2019-08-23 2023-10-24 深圳云合医药科技合伙企业(有限合伙) 胆汁酸衍生物及其组合物和应用
EP4041722A4 (en) 2019-10-07 2023-12-13 Kallyope, Inc. GPR119 AGONISTS
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
CN116323608A (zh) 2020-05-19 2023-06-23 卡尔优普公司 Ampk活化剂
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
KR102693566B1 (ko) * 2020-07-03 2024-08-08 주식회사 큐라클 지방간 질환의 예방 또는 치료를 위한 약학적 조성물
CN113774142A (zh) * 2021-10-11 2021-12-10 北京化工大学 Tgr5在制备治疗肠癌药物及诊断性试剂盒中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101554B1 (en) 1982-07-29 1986-10-15 Lehner A.G. New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
IT1206112B (it) 1983-04-29 1989-04-14 Lehner Ag Nuovi derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
IT1212835B (it) 1983-08-18 1989-11-30 Lehner Ag Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
US4892868A (en) * 1984-08-17 1990-01-09 Gipharmex, S.P.A. Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions
IT1196377B (it) 1984-12-21 1988-11-16 Lehner Ag Derivati di acidi biliari,procedimento per la loro preparazione e relative composizioni farmaceutiche
IT1223313B (it) * 1987-10-20 1990-09-19 Gipharmex Spa Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono
IT1229570B (it) * 1989-04-17 1991-09-04 Giuliani Spa Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
US5175320A (en) * 1989-04-17 1992-12-29 Giuliani S.P.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE69018592T2 (de) * 1989-12-13 1995-10-05 Mitsubishi Chem Corp Pyrazolylacrylsäure-Derivate, verwendbar als systemische Fungiziden in Pflanzen- und Materialschutz.
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US5689791A (en) 1996-07-01 1997-11-18 Xerox Corporation Electrically conductive fibers
CN1230114A (zh) 1996-07-12 1999-09-29 史密丝克莱恩比彻姆有限公司 Leptine抵抗的新疗法
US6008237A (en) * 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
US6200995B1 (en) 1998-01-29 2001-03-13 Tularik Inc. PPAR-γ modulators
AU1229000A (en) 1998-10-23 2000-05-15 Glaxo Group Limited Assays for ligands for nuclear receptors
US6639078B1 (en) * 1998-12-23 2003-10-28 Smithkline Beecham Corporation Assays for ligands for nuclear receptors
AU2409600A (en) 1999-01-07 2000-07-24 Tularik Inc. Fxr receptor-mediated modulation of cholesterol metabolism
JP2004510682A (ja) 1999-03-26 2004-04-08 シティ・オブ・ホープ 核胆汁酸受容体を用いコレステロール異化作用に影響を与える方法
EP1473042B1 (en) 1999-03-26 2006-06-21 City of Hope Screening for FXR receptor modulators
US20020132223A1 (en) * 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
AU768806B2 (en) 1999-06-11 2004-01-08 Allergan, Inc. Methods for modulating FXR receptor activity
US6906057B1 (en) * 1999-06-11 2005-06-14 Allergan, Inc. Methods for modulating FXR receptor activity
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
CA2386750A1 (en) 1999-10-22 2001-05-03 Merck & Co. Inc. Pharmaceuticals for treating obesity
WO2001077325A1 (fr) 2000-04-12 2001-10-18 Takeda Chemical Industries, Ltd. Nouvelle proteine de recepteur couple aux proteines g et adn de celle-ci
US6627636B2 (en) * 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
US20020119958A1 (en) 2001-02-13 2002-08-29 Shinichiro Tojo Therapeutic agent for hyperlipidemia
DK1392714T3 (da) * 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
EP1378749A4 (en) 2001-04-12 2005-05-11 Takeda Pharmaceutical SCREENING METHOD
WO2003016280A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
EP1285914B1 (en) 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Nr1h4 nuclear receptor binding compounds
WO2003015777A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
US20030144360A1 (en) 2001-11-19 2003-07-31 Allergan Sales, Inc. Composition and method for modulating BAR/FXR receptor activity
AU2003225903A1 (en) 2002-03-21 2003-10-08 Curagen Corporation Methods of using farnesoid x receptor (fxr) agonists
CA2482195A1 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
US6987121B2 (en) * 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
WO2004000752A1 (ja) 2002-06-19 2003-12-31 Availvs Corporation 人造石壁材
ITMI20021532A1 (it) 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici
JP2006515838A (ja) 2002-11-22 2006-06-08 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
EP1591120A4 (en) 2003-01-28 2009-06-10 Takeda Chemical Industries Ltd RECEPTOR AGONISTS
US20070015796A1 (en) 2003-09-26 2007-01-18 Smithkline Beecham Corporation Compositions and methods for treatment of fibrosis
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
DK1734970T3 (en) 2004-03-12 2015-02-16 Intercept Pharmaceuticals Inc Treatment of fibrosis using FXR ligands
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
EP2040713B1 (en) 2006-06-27 2014-06-18 Intercept Pharmaceuticals Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
EP1947108A1 (en) 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
KR101555716B1 (ko) 2007-01-19 2015-09-25 인터셉트 파마슈티컬즈, 인크. Ｔｇｒ5 조절제로서의 23-치환 담즙산 및 이의 사용 방법
PL2698375T3 (pl) * 2008-11-19 2018-08-31 Intercept Pharmaceuticals, Inc. Modulatory TGR5 i sposób ich zastosowania

Similar Documents

Publication Publication Date Title
JP2012509348A5 (enExample)
JP2012514009A5 (enExample)
EP2698375A3 (en) TGR5 modulators and method of use thereof
JP2009502793A5 (enExample)
JP2009545527A5 (enExample)
Pirollo et al. Antisense therapeutics: from theory to clinical practice
JP2013507439A5 (enExample)
JP2009502743A5 (enExample)
JP2014515013A5 (enExample)
JP2012509349A5 (enExample)
JP2010515715A5 (enExample)
JP2011520965A5 (enExample)
JP2011527332A5 (enExample)
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
JP2007045829A5 (enExample)
JP2014511863A5 (enExample)
JP2009543799A5 (enExample)
JP2014526441A5 (enExample)
JP2008533007A5 (enExample)
JP2011528658A5 (enExample)
JP2007302689A5 (enExample)
JP2011505356A5 (enExample)
JP2015527355A (ja) 体液貯留又は塩過負荷に関係する疾患及び消化管疾患の治療におけるｎｈｅ仲介の逆輸送を阻害するための化合物並びに方法
JP2011519871A5 (enExample)
JP2019510081A5 (enExample)